Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 715-721

  Danen van Oorschot, Astrid A ^a   Kuipers, Jenny E ^a   Arentsen Peters, Susan ^a   Schotte, Diana ^a   de Haas, Valerie ^b   Trka, Jan ^c   Baruchel, André ^d   Reinhardt, Dirk ^e   Pieters, Rob ^a   Michel Zwaan, C ^a   van den Heuvel Eibrink, Marry M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Dutch Childhood Oncology Group DCOG   (Netherlands)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d SAINT LOUIS HOSPITAL   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

MiR 155; MiR 196; MiR 29a; MiRNAs; Pediatric AML

Indexed keywords

CD135 ANTIGEN; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HOMEODOMAIN PROTEINS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS;

EID: 84857870463     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23279     Document Type: Article

References (43)

1. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 49-64.
2. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: Towards high-quality cure of all patients. Haematologica 2007; 92: 1519-1532.
3. Manola KN. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009; 83: 391-405.
4. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.
5. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
6. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group report of three consecutive trials. Leukemia 2005; 19: 2090-2100.
7. Smith FO, Alonzo TA, Gerbing RB, et al. Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054-2062.
8. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Pediatr Clin North Am 2008; 55: 21-51, ix.
9. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113: 5951-5960.
10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
11. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 2007; 104: 19971-19976.
12. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
13. Le Beau MM, Espinosa R III, Davis EM, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930-1935.
14. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
15. Debernardi S, Skoulakis S, Molloy G, et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007; 21: 912-916.
16. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945-3950.
17. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
18. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111: 5078-5085.
19. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928.
20. Han YC, Park CY, Bhagat G, et al. MicroRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 2010; 207: 475-489.
21. Mott JL, Kobayashi S, Bronk SF, et al. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140.
22. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590-11593.
23. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-7029.
24. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-594.
25. Schotte D, Lange-Turenhout EA, Stumpel DJ, et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 2010; 95: 1675-1682.
26. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304: 594-596.
27. Kaspers GJ, Veerman AJ, Pieters R, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052.
28. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322-4328.
29. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447-1452.
30. Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009; 23: 262-270.
31. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
32. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
33. Balgobind BV, van den Heuvel-Eibrink MM, Menezes RX, et al. Evaluation of gene expression signatures predictive for cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011; 96: 221-230.
34. Tissing WJ, Meijerink JP, Brinkhof B, et al. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood 2006; 108: 1045-1049.
35. John B, Enright AJ, Aravin A, et al. Human microRNA targets. PLoS Biol 2004; 2: e363.
36. Luthra R, Singh RR, Luthra MG, et al. MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008; 27: 6667-6678.
37. Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia 2008; 22: 2041-2047.
38. Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007; 21: 2000-2009.
39. Popovic R, Riesbeck LE, Velu CS, et al. Regulation of miR-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009; 113: 3314-3322.
40. Velu CS, Baktula AM, Grimes HL. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009; 113: 4720-4728.
41. Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331-5341.
42. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. Blood 2009; 114: 2489-2496.
43. Georgantas RW III, Hildreth R, Morisot S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755.